logo-loader
viewProactive Group

PDS Biotechnology shares pop on positive medical journal article

The article explains how Versamune, the company’s cancer immunotherapy platform, activates T-cells to identify and attack cancer cells

Blood cells
The article explored how Versamune, the company’s cancer immunotherapy platform, activates T-cells to identify and attack cancer cells

Shares of PDS Biotechnology Corporation (NASDAQ:PDSB) exploded Wednesday on news that an article supporting its signature cancer treatment platform will be published in the Journal of Immunology’s June issue.

The article explains how Versamune, the company’s cancer immunotherapy platform, activates T-cells to identify and attack cancer cells, while making the cancer cells more vulnerable to attack.

The New Jersey company’s stock soared 43% to US$8.80.

The piece examines a preclinical study conducted at University of Kentucky School of Medicine, which corroborated the results of earlier preclinical studies regarding the immunological activity of PDS’ proprietary lipid molecule.

"As a cancer immunologist who has spent the last decade performing translational and clinical research in immuno-oncology at the National Cancer Institute, the versatility of PDS’ Versamune technology, and the strength of this recently published data, demonstrates Versamune’s potential to provide significant advancements in the treatment of various cancers and debilitating diseases,” said Chief Medical Officer Lauren Wood. 

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Global Energy Metals in London discussing plans to develop cobalt projects...

Global Energy Metals Corporation (CVE:GEMC) (OTCMKTS:GBLEF) CEO Mitchell Smith caught up with Proactive's Andrew Scott while in London to update shareholders on progress within its portfolio of cobalt and battery metal projects. Smith says the firm's well-placed to take advantage of the...

8 hours, 2 minutes ago

2 min read